DNA methylation microarrays identify epigenetically regulated lipid related genes in obese patients with hypercholesterolemia

Teresa Płatek1*, Anna Polus1, Joanna Góralsk1, Urszula Rażyń1, Anna Gruca1, Beata Kieć-Wilk2, Piotr Zabielski4, Maria Kapusta1, Krystyna Słowińska-Solnica1, Bogdan Solnica1, Małgorzata Malczewska-Malec1 and Aldona Dembińska-Kieć1

Abstract

Background: Epigenetics can contribute to lipid disorders in obesity. The DNA methylation pattern can be the cause or consequence of high blood lipids. The aim of the study was to investigate the DNA methylation profile in peripheral leukocytes associated with elevated LDL-cholesterol level in overweight and obese individuals.

Methods: To identify the differentially methylated genes, genome-wide DNA methylation microarray analysis was performed in leukocytes of obese individuals with high LDL-cholesterol (LDL-CH, ≥ 3.4 mmol/L) versus control obese individuals with LDL-CH, < 3.4 mmol/L. Biochemical tests such as serum glucose, total cholesterol, HDL cholesterol, triglycerides, insulin, leptin, adiponectin, FGF19, FGF21, GIP and total plasma fatty acids content have been determined. Oral glucose and lipid tolerance tests were also performed. Human DNA Methylation Microarray (from Agilent Technologies) containing 27,627 probes for CpG islands was used for screening of DNA methylation status in 10 selected samples. Unpaired t-test and Mann–Whitney U-test were used for biochemical and anthropometric parameters statistics. For microarrays analysis, fold of change was calculated comparing hypercholesterolemic vs control group. The q-value threshold was calculated using moderated Student's t-test followed by Benjamini–Hochberg multiple test correction FDR.

Results: In this preliminary study we identified 190 lipid related CpG loci differentially methylated in hypercholesterolemic versus control individuals. Analysis of DNA methylation profiles revealed several loci engaged in plasma lipoprotein formation and metabolism, cholesterol efflux and reverse transport, triglycerides degradation and fatty acids transport and β-oxidation. Hypermethylation of CpG loci located in promoters of genes regulating cholesterol metabolism: PCSK9, LRP1, ABCG1, ANGPTL4, SREBF1 and NR1H2 in hypercholesterolemic patients has been found. Novel epigenetically regulated CpG sites include ABCG4, ANGPTL4, AP2A2, AP2M1, AP2S1, CLTC, FGF19, FGF1R, HDLBP, LIPA, LMF1, LRPS, LSR, NR1H2 and ZDHHC8 genes.

Conclusions: Our results indicate that obese individuals with hypercholesterolemia present specific DNA methylation profile in genes related to lipids transport and metabolism. Detailed knowledge of epigenetic regulation of genes, important for lipid disorders in obesity, underlies the possibility to influence target genes by changing diet and...
Background
The worldwide prevalence of obesity nearly tripled between 1975 and 2016 and is still growing, contributing to an increased incidence of comorbidities such as type 2 diabetes, dyslipidemia, liver steatosis, hypertension, cardiovascular disease (CVD) and cancer (Blüher 2019). Metabolic complications of obesity include insulin resistance, impaired secretion and action of incretin hormones, disturbed plasma lipoprotein clearance and metabolism and low grade inflammation (Pedersen 2013; Chia and Egan 2020; Magkos et al. 2008; Ellulu et al. 2016). A number of factors can play a role in weight gain. Among them, the most powerful factors seem to be an unhealthy lifestyle and genetics (Albuquerque et al. 2017). Research over the last decade indicates that various environmental factors at different stages of life can changes to chromatin structure and function and thus change cellular phenotype and metabolism (Rosen et al. 2018; Piening et al. 2018; Jacobsen et al. 2012; Stuart et al. 2018; Roh et al. 2018). Epigenetic modifications such as DNA methylation and multiple histone post-translational modifications regulate gene transcription and thus adapt metabolism to environmental factors (Handel et al. 2010; Keating and El-Osta 2015). It is estimated that 70% of promoters in human genomes are rich in CpG sites indicating that DNA methylation serves as a crucial epigenetic modification (Blattler and Farnham 2013). DNA methylation of CpG sites in the genes’ promoters as well as distal regulatory sites may modify gene expression by altering the interaction of histones, thereby affecting the binding of transcription factors or recruitment of methyl-CpG binding proteins (MBPs) (Rottach et al. 2009; Handel et al. 2010). Methylation of CpG dinucleotides may be reversible, modified in response to environmental factors consequently repressing or activating transcription (Blattler and Farnham 2013; Handel et al. 2010; Abdul et al. 2017). Current scientific reports show that methylation of CpG islands influences the expression of genes related to obesity, metabolic syndrome and type 2 diabetes (Kim et al. 2015; Ali et al. 2016; Shen and Zhu 2018; Guo et al. 2020). We hypothesize that several processes regulating lipid levels are controlled by DNA methylation. Therefore, this study aimed to investigate the differences in DNA methylation status in leukocytes of obese subjects with hypercholesterolemia compared to controls. Here we present the results of an analysis of a genome-wide methylation profile, with focus on genes involved in lipids metabolism to find the pathways mostly affected by hypercholesterolemia and find new candidates genes. The results of this work may contribute to a better understanding of the epigenetic mechanisms related to dyslipidemia.

Methods
Aim of the study
The study aims to elucidate the link between epigenetic changes and hypercholesterolemia in obese patients.

Patients
Our cohort involved 137 individuals with BMI (body mass index) above normal range (min.27–max.45 kg/m²), women (n = 99) and men (n = 38), aged 25 to 65 years. Exclusion criteria included cardiovascular diseases, diabetes mellitus, kidney or liver failure, endocrine disorders, chronic inflammation, hormone therapy, use of lipid-lowering or anti-inflammatory drugs, use of diet supplements, smoking or excessive use of alcohol, pregnancy or lactation.

The hypercholesterolemia group, (n = 68) consisted of patients with obesity with borderline high, or high serum LDL cholesterol (LDL-CH) levels (≥ 3.4 mmol/L) and the control group (n = 69) consisted of obese subjects with serum LDL-CH levels <3.4 mmol/L (Stone et al. 2013). At this cut-off point the control group included patients with optimal for low CV risk [< 3.0 mmol/L according to recent ESC/EAS 2019 guidelines (Mach et al. 2019)] as well as near-optimal LDL-CH concentration (3.0–3.4 mmol/L). The main criteria of enrolment into study groups were: overweight or obesity without comorbidities requiring treatment (except hypertension treated with AT1 receptor antagonists or calcium channel blockers) and fasting LDL-CH ≥ 3.4 mmol/L (group with newly diagnosed hypercholesterolemia) or LDL-CH <3.4 mmol/L (control group).

From the cohort 10 samples representative for both groups were selected for the study of DNA methylation on microarrays.

Anthropometric parameters and blood pressure
Anthropometric parameters: body weight, height, waist and hip circumferences were measured and BMI, waist to hip ratio (WHR) were calculated. Body fat percentage was estimated by bioelectrical impedance method using the Segmental Body Composition Analyzer TANITA BC
418 MA. Blood pressure was measured after 10 min of rest.

Sample collection
Fasting venous blood samples were collected and centrifuged (1000 × g for 10 min at 4 °C within 30 min from collection) for serum and plasma separation. Serum and plasma samples were immediately frozen and stored at −80 °C for further analyses of glucose, insulin, adipokines (leptin and adiponectin), glucose-dependent insulinotropic peptide (GIP), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), total cholesterol, HDL (high density lipoprotein)-cholesterol, triglycerides (TGs), total plasma fatty acids content and composition. For analysis of DNA methylation fasting peripheral blood was collected into K2-EDTA-containing tubes and stored at −80 °C until analysed.

Oral glucose tolerance test (OGTT) and oral lipid tolerance test (OLTT) were performed on separate days. Venous blood samples: fasting, 30, 60, 90 and 120 min of OGTT as well as fasting (before meal), 2, 4, 6, and 8 h of OLTT were collected in order to measure postprandial glucose, insulin, GIP and TG serum concentrations. OLTT- an 8-h high fat mixed meal tolerance test that contained 73% fat, 16% protein, and 11% carbohydrates, with a caloric value of 1018 kcal was performed. The detailed composition of meal was described previously (Razny et al. 2018).

Biochemical tests
Serum glucose, total cholesterol, HDL cholesterol, and TGs were measured using enzymatic colorimetric methods on the MaxMat analyzer (MaxMat S.A., Montpellier, France). LDL cholesterol concentration was calculated using the Friedewald formula. Serum insulin was determined by immunoradiometric method (Diasource, ImmunoAssays, Belgium). Serum leptin, adiponectin, FGF19 and FGF21 were measured using ELISA (Human Leptin Quantikine ELISA kit; Human Total Adiponectin/Acrp30 Quantikine ELISA kit; Human FGF-19 Quantikine ELISA Kit; Human FGF-21 Quantikine ELISA Kit, respectively, R&D Systems Inc. Minneapolis, MN, USA). GIP was measured by ELISA [Human GIP (Total) ELISA kit (EMD Millipore, St Charles, MO, USA)]. Total plasma fatty acids content and composition was measured by gas–liquid chromatography and flame-ionization detector after direct in situ transesterification, according to Glaser et al. (2010). Plasma fatty acids profile included quantitative determination of saturated (myristic, palmitic, stearic, behenic, lignoceric, and arachidic), monounsaturated (palmitoleic, oleic and nervonic) and polyunsaturated (arachidonic, linoleic, α-linolenic, eicosapentaenoic, and docosahexaenoic) fatty acids.

DNA methylation screening analysis
To perform DNA methylation screening, taking into account that both groups of hypercholesterolemia and control were equal-sized, five samples for microarrays analyses were randomly selected from each of them. To reduce the difference between structure of participants in two original groups and their random subsamples, randomization was carried out in sex stratas in proportions of women to men 3:2 to map numerical superiority of men in our study (99 women versus 38 men). We didn’t consider any other sampling strata given the limited sample size of a participants on which we could measure genome wide methylation. Drawn individuals in hypercholesterolemic and control groups were balanced by age and BMI.

Methylation screening analysis with immunoprecipitation of methylated DNA and hybridization to Human DNA Methylation Microarray
Genomic DNA from venous blood was extracted using the High Pure PCR Template Preparation Kit (ROCHE Diagnostics, Mannheim, Germany). The measurement of DNA quantity and quality was performed by spectrophotometry using the NanoDrop ND1000. An amount of 5 µg of DNA was taken for sonication. Sonication efficiency was assessed by electrophoresis on a 2.0% agarose gel. The sonicated DNA sample was then divided into two aliquots: four parts of DNA were taken for immunoprecipitation, the fifth part was stored as a reference input fraction. Analysis of methylated DNA was done by immunoprecipitation of DNA containing 5-methylcytosines (5-mC) using monoclonal antibodies against 5-methylcytidine (Monoclonal Antibody to 5-Methyl Cytosine/5-MeC Purified from Acris Antibodies, Inc, USA). Immunoprecipitated and reference samples were labelled with fluorescent dyes Cyanine-3 and Cyanine-5, respectively. The exact steps were performed based on the methodology of Agilent Technologies. Competitive hybridization of input material and methylated enriched DNA was performed to oligonucleotide microarrays—Human DNA Methylation Microarray (G4495A, Design ID, 023795) from Agilent Technologies. High-definition 244 K arrays contained 27,627 probes for annotated human CpG islands and 5081 for Undermethylated Regions (UMRs). Microarrays were hybridized for 40 h at 65 °C. Slides washing and scanning procedures and image extraction using Agilent Features Extraction software v 10.10.1.1 were performed according to the manufacturer instructions.
Statistical analyses
For biochemical and anthropometric parameters, Shapiro–Wilk test was used to assess normality of distribution of continuous variables, then unpaired t-test for normally distributed data and Mann–Whitney U-test for non-normally distributed data were used for comparison of the two groups. The Chi-squared test was used for nominal variables. Normally distributed data are shown as mean ± standard deviation (SD), otherwise as median (Q2) and interquartile range in parentheses (Q1; Q3). All analyses were performed with the Statistica 13 software (StatSoft). The p-value < 0.05 was considered statistically significant.

Microarray data analysis was performed using the Feature extraction software v 10.10.1.1 (Agilent Technologies, Santa Clara, USA), the BRB-ArrayTools Version 4.6 software (National Institutes of Health, Bethesda, MD, USA), R programming language (R Foundation for Statistical Computing, University of Auckland, New Zealand) and the Gene Spring version 13 software (Agilent Technologies, Santa Clara, USA). Feature extraction software was used to assess background subtracted intensity values for the two fluorescence dyes on each individual array feature and calculated as the ratio (Cy3/Cy5). We used Lowess normalization method for dual channel raw hybridization signals and background correction to median of all samples. A quality analysis was performed for each sample array taken for analysis (QC reports evaluation). Regarding methylation sites we removed bad quality probes, probes not located in CpG islands, probes containing SNPs in the CpG site and removed probes located on X and Y chromosomes. To account for potential differences in the proportions of blood cells, we estimated the proportion of Lymphocytes, Monocytes, Eosinophils, Basophils and Neutrophils to adjust raw data as previously described by Houseman et al. in R (Houseman et al. 2014). Fold of change was calculated for the hypercholesterolemic group in relation to the control group and shown as methylation level. The p-value threshold was calculated using statistical filtering (moderated Student’s t-test followed by Benjamini–Hochberg multiple test correction FDR-q-value). Loci corresponding to a q-value of <0.05 and fold change of either >1.3 or <-1.3 were classified as differentially methylated. Highly methylated regions had ratios significantly above zero while less methylated regions had log ratios significantly below zero.

Pathways analysis was performed in Reactome Pathway to obtained the list of differentially methylated genes related to lipids pathways (Sidiropoulos et al. 2017). Subsequently we used the BiNGO plugin in Cytoscape software (version 3.7.2) to assessed the involvement of selected genes in biological processes and molecular function (Maere et al. 2005). We used parameters as: overrepresentation after correction (using statistical test as hypergeometric test with multiple testing correction as Benjamini and Hochberg False Discovery Rate (FDR) correction). Results with corrected p-value < 0.05 are presented in manuscript.

Results
Biochemical and anthropometric characteristics of groups
The studied group of patients with high serum LDL-CH was comparable to the control group in terms of weight, BMI, WHR, blood pressure and adipose tissue mass. The hypercholesterolemic group showed not only higher LDL-CH but also total cholesterol, triglycerides, non-HDL-CH compared to the control group (Table 1). Total plasma fatty acids content and saturated fatty acids content were higher in the high LDL-CH group as well. Particularly, higher content of palmitoleic acid (mean 1.33 (µg/mL) ±0.18 vs mean 0.84 (µg/mL) ±0.34, p = 0.0352) was observed in hypercholesterolemic group. Additionally, higher percentage of myristic acid (mean 0.87 (%) ±0.79 vs mean 0.35 (%) ±0.15, p = 0.188) in this group was noted.

Fasting serum TG levels were higher in the hypercholesterolemic patients. Obese subjects had fasting glucose below the upper reference limit, though slightly higher values of serum glucose were observed in the dyslipidemic patients compared to control. Subjects with high plasma LDL-CH were also characterized by higher FGF21 and lower adiponectin (presenting trend toward significance) serum levels (Table 1).

As the group studied in terms of methylation was a representative part of the larger cohort, below we present the characteristics of the entire cohort in Table 2. The trends and directions of differences between microarray subgroups have been preserved for those parameters that differed significantly in large groups, especially the proportions of fatty acid groups and the concentrations of GIP, FGF19 and FGF21 proteins.

The results of differential methylation analysis
In this preliminary study, we identified 7480 differentially methylated CpG sites, including 4905 CpG hypermethylated and 2575 hypomethylated sites. Data analysis in the Reactome Pathway Browser revealed engagement of 188 CpG probes, located in 143 genes in pathways related to lipid metabolism. The most interesting finding is the different methylation pattern of genes involved in: (1) lipoprotein assembly, remodeling and clearance (Fig. 1); (2) regulation of lipid metabolism by peroxisome proliferator-activated receptor alpha (PPARα); (3) regulation of cholesterol biosynthesis by sterol regulatory element binding protein (SREBP); (4)
fatty acid metabolism and (5) triglyceride metabolism. In leukocytes of patients with elevated serum LDL-CH, we found hypomethylated promoters of the following genes involved in lipoprotein metabolism: LPL, LIPA, ZDHHC8, PRKACA, AMN and FGF19; hypermethylated promoters of PCSK9, ABCG1, CLTC, AP2M1, AP2S1, LMFI1, LSR, PRKACG, ANGPTL4, NR1H2, and PCSK5, and hypermethylated inside the following genes: LDLR, HDLBP, AP2A2 and PCSK6 (Fig. 1 and Additional file 1: Table S1).

Enrichment analysis using BiNGO application showed possible involvement of genes in biological processes and identified probable molecular function. Results are presented in Table 3. Interestingly, the affected pathways in the group of obese with hypercholesterolemia included (1) lipoprotein remodeling in plasma (with hypomethylated promoter of LPL and hypermethylated ABCG1 and ABCA5); (2) regulation of cholesterol storage (with hypomethylated promoters of LPL and PPARG, and hypermethylated ABCG1 and NR1H2); and (3) cholesterol transport (with hypomethylated promoter of LIPA and hypermethylated ABCA5, ABCG1 and ABCG4—responsible for cholesterol efflux) (Table 3a). Other genes differentially methylated were associated with (1) fatty acids biosynthesis (hypermethylated: ELOVL3, ELOVL5, and ELOVL6, and hypomethylated: FASN, LPL, MLYCD and MCAT); (2) fatty acid transport (hypermethylated: ACSL6 and hypomethylated: PPARD, PPARG, SLC25A20 and SLC27A1); and (3) fatty acid β-oxidation (hypermethylated: ACADM and CPT1A and hypomethylated: AMN, CRAT and PPARD). Some genes related to glucose homeostasis were also found to be hypermethylated: FOXO3, NCOR2, TCF4 and TCF7L2, contrary to PPARG which was hypomethylated (Table 3a). The BiNGO plugin revealed probable molecular function of a set of genes as lipid binding, receptor binding, transporter activity and transcription factor binding (Table 3b).

### Table 1 Characteristics of subjects selected for DNA methylation analysis

|                      | Hypercholesterolemia group (n = 5) | Control group (n = 5) | p-value |
|----------------------|------------------------------------|-----------------------|---------|
| Age (years)          | 43.0 ± 12.6                        | 44.6 ± 10.6           | 0.83    |
| Sex, female (%)b     | 60                                 | 60                    | ns      |
| Weight (kg)³         | 88 (80–107.7)                      | 89.2 (80.2–103.2)     | 1       |
| Adipose tissue mass (%)a | 38.3 (30.55–43.25)            | 37.4 (30.9–45.3)      | 0.47    |
| BMI (kg/m²)          | 34.0 (29.47–36.9)                  | 31.7 (28.4–38.9)      | 0.676   |
| WHR²                 | 0.9 (0.81–0.95)                    | 0.81 (0.79–0.82)      | 0.11    |
| Systolic blood pressure (mmHg)⁴ | 130 (127.5–140)                | 124 (119–130)         | 0.095   |
| Diastolic blood pressure (mmHg)⁴ | 80 (80–90)                    | 80 (77–86)            | 0.53    |
| Total cholesterol (mmol/L)⁴ | 6.31 (5.58–6.64)                | 5.0 (4.5–5.25)        | 0.06    |
| LDL cholesterol (mmol/L)⁴ | 4.27 (3.9–4.8)                  | 2.74 (2.5–2.95)       | <0.001  |
| HDL cholesterol (mmol/L)⁴ | 1.2 ± 0.3                     | 1.4 ± 0.3             | 0.25    |
| Non-HDL (mmol/L)⁴    | 5.19 (4.53–5.57)                  | 3.49 (2.99–4.11)      | 0.02    |
| Fasting triglycerides (mmol/L) | 1.7 ± 0.7                    | 1.1 ± 0.8             | 0.26    |
| Total fatty acids (µg/mL) | 41.18 ± 1226                   | 33.14 ± 925           | 0.31    |
| Saturated fatty acids (%) | 34.04 ± 1.96                   | 32.09 ± 0.85          | 0.08    |
| Monounsaturated fatty acids (%) | 28.52 ± 4.35                  | 26.42 ± 4.42          | 0.49    |
| Polyunsaturated fatty acids (%) | 37.43 ± 6.02                  | 41.49 ± 4.37          | 0.28    |
| Fasting glucose (mmol/L)⁴ | 5.8 (5.1–6.3)                  | 4.9 (4.7–5.8)         | 0.4     |
| Glucose AUC OLT (mmol/L.min)⁴ | 10.44 (10.0–10.72)              | 9.05 (8.78–9.77)      | 0.022   |
| Glucose AUC OGTT (mmol/L.min)⁴ | 4.4 (3.2–5.0)                  | 3.26 (2.6–3.45)       | 0.06    |
| Fasting insulin (µIU/mL) | 22.8 ± 16.8                   | 11.3 ± 4.2            | 0.173   |
| HOMA-IR              | 4.0 ± 1.6                        | 2.6 ± 1.1             | 0.14    |
| Adiponectin (µg/mL)³  | 4.2 (3.55–8.07)                  | 7.4 (5.58–10.00)      | 0.21    |
| Leptin (ng/mL)³      | 29.89 (15.18–46.04)              | 21.8 (14.16–101.85)   | 0.83    |
| Fasting GIP (pg/mL)³ | 32.54 (12.3–48.8)                | 24.1 (18.1–37.43)     | 0.4     |
| FGF19 (pg/mL)        | 160.8 ± 61.7                     | 151.4 ± 108.7         | 0.62    |
| FGF21 (pg/mL)        | 280.4 ± 144.3                    | 138.8 ± 92.5          | 0.102   |

Comparison between the high LDL-CH group and controls (unpaired t-test for normally or Mann–Whitney U-test for non-normally distributed a variables). Data shown as mean ± SD; otherwise (*) as median and interquartile range in parentheses except nominal variable (b) shown as % of subjects. b The chi-squared test was used for nominal variable. The statistically significant results are marked in italics.
In our study, hypermethylation of promoters of key genes regulating cholesterol metabolism such as PCSK9, LRP1, ABCG1, ANGPTL4, SREBF1 and NR1H2, were found in obese patients with hypercholesterolemia. Furthermore, enhanced methylation of promoters of genes coding for transcription factors, such as NFKB2, TCF4, GATA4, INSM1, CTCF, TCF7L2 and SREBF1 and reduced methylation of KLF14, PPARD and PPARG, were found (Table 3a, b).

Locations of CpG sites in genes are presented in Additional file 1: Table S1.

**Discussion**

This preliminary study showed different DNA methylation profiles in the leukocytes of obese, hypercholesterolemic patients (LDL-CH ≥ 3.4 mmol/L, n = 5) compared to the leukocytes methylome of obese subjects presenting serum LDL-CH levels < 3.4 mmol/L (n = 5). Main finding of this study is the identification of differentially methylated genes associated with lipid metabolism pathways. Among the lipid-related genes mostly significant were the following pathways: regulation of lipid metabolism by PPAR alpha; plasma lipoprotein assembly, remodeling, and clearance; metabolism of lipids; regulation of gene expression by SREBP, PPARA and NR1H2; LDL clearance and VLDLR internalisation and degradation (all located in the top ten of mostly significant pathways).

We have presented new loci of differential DNA methylation in genes that were previously found to be associated with dyslipidemia (ABCG1, CPT1A, FASN, KLF14, LDLR, LPL, LRP1, PCSK9, PPARG and SREBF1) (Mittelstraß and Waldenberger 2018; Pfeiffer et al. 2015; Rohde et al. 2019; Campanella et al. 2018) but also in new candidate genes, potentially related to...
hypercholesterolemia. Novel epigenetically regulated genes include \textit{ABCG4}, \textit{ANGPTL4}, \textit{AP2A2}, \textit{AP2M1}, \textit{AP2S1}, \textit{CLTC}, \textit{FGF19}, \textit{FGF1R}, \textit{HDLBP}, \textit{LIPA}, \textit{LMF1}, \textit{LRP5}, \textit{LSR}, \textit{NR1H2} and \textit{ZDHHHC8}. The unique set of differentially methylated genes were enriched in gene ontology to cholesterol and fatty acid metabolism, especially plasma lipoprotein formation and metabolism, reverse cholesterol transport, triglycerides degradation, fatty acids transport and β-oxidation.

Regarding lipoprotein assembly, remodeling and clearance, the reduced methylation in promoters of genes coding for \textit{LPL} (Lipoprotein lipase), \textit{LIPA} (Lipase A) and \textit{ZDHHHC8} (Zinc Finger DHHC-Type Containing 8) were found. Palmitoyl transferase \textit{ZDHHHC8} mediates palmitoylation of \textit{ABCA1} and thus localization of this cholesterol transporter at the plasma membrane (Singaraja et al. 2009). Methylation of promoter of \textit{LPL} gene in leukocytes and visceral adipose tissue was previously published in severe obese men (Guay et al. 2013). In this paper the association between \textit{LPL} DNA methylation and \textit{LPL} mRNA level in visceral adipose tissue and HDL cholesterol (HDL-CH) level was presented (Guay et al. 2013).

We detected hypomethylation in \textit{FGF19} and \textit{FGFR1} genes in leukocytes DNA of obese patients with hypercholesterolemia. The effect of \textit{FGF19} on TG and cholesterol levels may vary depending on the type of \textit{FGFR1} or \textit{FGFR4} receptor with which it interacts (Wu et al. 2013). Zhou et al. (2019) demonstrated that \textit{FGF19} promotes HDL biogenesis and cholesterol efflux from the liver, with increasing serum HDL and LDL cholesterol as a consequence.

The next set of genes found to be hypermethylated in our hypercholesterolemic patients: \textit{PCSK9}, \textit{CLTC}, \textit{AP2A2}, \textit{AP2M1} and \textit{AP2S1}, are involved in the endocytosis of the ligand-bound LDL and VLDL receptors (Peterson et al. 2008; Mulkerns and Cooper 2012; Go and Mani 2012; Pearse et al. 2000). Although \textit{PCSK9} is principally expressed in the liver, \textit{PCSK9} gene promoter methylation is conserved across tissues and positively correlated with its expression (Lohoff et al. 2018). Recently it was found that \textit{FGF21} serves as a potential negative regulator of \textit{PCSK9} (Guo et al. 2016), which is in line with our observation that hypermethylation of \textit{PCSK9} corresponds with higher circulating \textit{FGF21} levels in patients with hypercholesterolemia compared to control subjects.

Our study found differential methylation of the following genes encoding receptors involved in lipoprotein trafficking: hypermethylated \textit{LDLR} (Low Density Lipoprotein Receptor), \textit{LRP1} (LDL Receptor Related Protein 1), \textit{LRP5} (LDL Receptor Related Protein 5), \textit{LSR} (Lipolysis Stimulated Lipoprotein Receptor) and \textit{NR1H2} (Nuclear Receptor Subfamily 1 Group H Member 2) and hypomethylated \textit{LRP8} (LDL Receptor Related Protein 8). \textit{LRP1} together with LDLR play an essential role in binding and internalization of apoE- and apoB-containing lipoproteins regulating their cellular uptake (Dato and Chiabrando 2018). It has been found that DNA methylation of the \textit{LRP1} gene (locus in 5’UTR) was previously detected in placental DNA and was correlated with maternal total cholesterol changes during pregnancy (Guay et al. 2020). In subsequent studies, a positive association between DNA methylation in \textit{LRP1} gene
### Table 3 Results of statistically overrepresented biological processes and molecular function in set of differentially methylated genes

| Description                                                                 | p-value     | Corr p-value | N   | Hypermethylated                                                                 | Hypomethylated                                                                 |
|----------------------------------------------------------------------------|-------------|--------------|-----|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| **a. Gene Ontology_Biological Processes**                                    |             |              |     |                                                                                |                                                                                |
| Lipid metabolic process                                                     | 6.061E−33   | 1.0849E−29   | 47  | ABCG1 ACADM ACSL6 AHRR CAV1 CPT1A ELOVL3 ELOVL5 ELOVL5 FDFT1 FDPS GPX1 GPX4     | ABCB4 ACOT1 ACOT7 ACSF2 AGPAT2 AMN CRAT CYP1B1 CYP27B1 CYP51A1 DHCR7 FASN IL6ST INSIG1 LIPA LPL LR8 MLYCD MCAT PPARD PPARG SLC27A1 SLC2A1 |
| Regulation of lipid biosynthetic process                                    | 1.823E−6    | 3.4005E−5    | 6   | ABCG1 ACSL6 NR1H2                                                             | DHC7 FG19 SLC27A1                                                              |
| Negative regulation of lipid biosynthetic process                           | 6.238E−3    | 2.5581E−2    | 2   |                                                                                | FGF19 SLC27A1                                                                  |
| Fatty acid metabolic process                                                | 9.26E−17    | 2.37E−14     | 19  | ACADM ACSL6 CPT1A ELOVL3 ELOVL5 ELOVL6 PPARA                                  | ACOT1 ACOT7 ACSF2 AMN CRAT FASN LPL MCAT MLYCD PPARD SLC27A1                   |
| Cholesterol metabolic process                                               | 6.73E−19    | 6.02E−16     | 16  | ABCG1 FDFT1 FDPS HDLBP LDLR PCSK9 PMVK RXRA SREBF1 SREBF1                     | CYP1A1 DHC7 FG19 SLC27A1                                                       |
| Triglyceride metabolic process                                              | 1.02E−08    | 4.81E−07     | 7   | ACSL6 CAV1 CPT1A PCSK9                                                       | IL6ST LIPA                                                                     |
| Cholesterol biosynthetic process                                            | 5.57E−07    | 1.49E−05     | 5   | FDFT1 FDPS PMVK                                                               | CYP51A1 DHC7                                                                     |
| Regulation of cholesterol storage                                          | 8.89E−09    | 4.42E−07     | 5   | ABCG1 NR1H2 PPARA                                                            | LPL PPARG                                                                       |
| Cholesterol transport                                                      | 2.01E−07    | 6.09E−06     | 6   | ABCAS ABCG1 ABCG4 CAV1 LDLR                                                    | LIP                                                                             |
| Cholesterol efflux                                                         | 1.00E−05    | 1.50E−04     | 4   | ABCAS ABCG1 ABCG4 CAV1                                                        |                                                                                |
| Reverse cholesterol transport                                               | 5.57E−03    | 2.37E−02     | 2   | ABCAS ABCG1                                                                   |                                                                                |
| Regulation of cholesterol transport                                        | 4.57E−04    | 3.38E−03     | 3   | NR1H2 LRP1                                                                   | PPAR                                                                          |
| Negative regulation of cholesterol storage                                  | 2.72E−08    | 1.08E−06     | 4   | ABCG1 NR1H2 PPARA                                                             | PPAR                                                                          |
| Fatty acid biosynthetic process                                             | 1.60E−06    | 3.12E−05     | 7   | ELOVL3 ELOVL5 ELOVL6                                                          | FASN LPL MLYCD MCAT                                                             |
| Fatty acid transport                                                       | 2.46E−08    | 1.05E−06     | 6   | ACASL6 PPARA                                                                 | PPARAD SLC25A20 SLC2A1                                                        |
| Fatty acid beta-oxidation                                                   | 1.22E−06    | 2.63E−05     | 5   | ACADM CPT1A                                                                   | AMIN CRAT PPARD                                                                |
| Regulation of fatty acid oxidation                                          | 2.39E−06    | 4.32E−05     | 5   | CPT1A PPARA                                                                   | MLYCD PPARG SLC25A20                                                          |
| Long-chain fatty acid metabolic process                                     | 1.90E−03    | 1.04E−02     | 2   | ACSL6                                                                       | ACOT1                                                                          |
| Regulation of macrophage derived foam cell differentiation                  | 1.52E−08    | 6.63E−07     | 6   | ABCAS ABCG1 NR1H2 PPARA                                                      | LPL PPARG                                                                      |
| Low-density lipoprotein receptor metabolic process                          | 4.37E−05    | 5.00E−04     | 2   | PCSK9                                                                       | PPARG                                                                          |
| Plasma lipoprotein particle remodelling                                     | 3.99E−04    | 3.11E−03     | 3   | ABCAS ABCG1                                                                  | LPL                                                                            |
| High-density lipoprotein particle remodelling                               | 3.77E−03    | 1.75E−02     | 2   | ABCAS ABCG1                                                                  |                                                                                |
| Regulation of steroid metabolic process                                     | 3.09E−03    | 1.52E−02     | 3   | ABCG1                                                                       | FGF19 DHC7                                                                     |
| Glucose homeostasis                                                        | 1.17E−06    | 2.58E−05     | 5   | FOXO3 NCO2 TCF4 TCF7L2                                                        | PPARG                                                                          |
| Response to glucose stimulus                                                | 6.04E−05    | 6.47E−04     | 4   | EP300 TCF7L2 TCF4                                                             | PPARD                                                                           |
| Regulation of insulin secretion                                             | 4.82E−04    | 3.50E−03     | 3   | CPT1A TCF4 TCF7L2                                                             |                                                                                |
| Carbohydrate homeostasis                                                   | 1.17E−06    | 2.58E−05     | 5   | FOXO3 NCO2 TCF4 TCF7L2                                                        | PPARG                                                                          |
| Regulation of response to stress                                            | 5.02E−05    | 5.65E−04     | 10  | AP2A2 AP2AP2 AP2M1 CAV1 GPX4                                                  | FGF19 IL6ST IRAK1 PPARG PRKACA                                                |
| Negative regulation of apoptosis                                           | 3.59E−03    | 1.70E−02     | 8   | ANGPTL4 NKX2-6 S1N3A PCSK6 TCF4 TCF7L2                                        | FGFR1 IRAK1                                                                    |
| **b. Gene Ontology_Molecular Function**                                     |             |              |     |                                                                                |                                                                                |
| Lipid binding                                                              | 2.19E−08    | 3.54E−06     | 15  | ABCG1 AP2A2 AP2M1 CAV1 HDLBP PPARRA RXRA S1PR4                                | ACOT7 ITPR1 LIPA PPARD PPARG SLC27A1                                           |
| Receptor binding                                                           | 1.99E−06    | 1.16E−04     | 19  | ANGPTL4 CAV1 EP300 LRP1 IL6ST IL13 NCOA2 NCO2 NR1H2 PCSK9 RXRA TCF4 TCF7L2 TGFβ11 | CD8A FGF19 IRAK1 LPL PPARG                                                    |
and HDL-CH level was demonstrated in patients with metabolic syndrome (Castellano-Castillo et al. 2019). However, the exact location of the CpG sites has not been shown in these articles. We demonstrated hypermethylation of CpG sites located inside the fourth exon of the LDL receptor (LDLR) gene, however the consequences of methylation of that region have not yet been reported. Guay et al. (2020) presented correlation with DNA methylation of that region have not yet been reported. Guay et al. (2020) presented correlation with DNA methylation in LDLR gene (CpG-A locus located between the fourth and fifth exon) with maternal total cholesterol level changes during pregnancy. Higher methylation degree of LDLR gene promoter in peripheral blood in atherosclerotic patients compared to healthy subjects was found (Zhi et al. 2007).

In presented study patients with elevated LDL-CH were characterized by hypermethylated CpG sites also within the promoters of the ABCG1, ABCA5, ABCG4 and CAV1 genes that are responsible for reverse cholesterol transport (Mauldin et al. 2008; Vaughan and Oram 2006). Pfeiffer et al. showed the association of CpG methylation in ABCG1 (cg06500161, 21:43656587) with HDL cholesterol and triglycerides level in 1776 subjects in the KORA F4 cohort (Pfeiffer et al. 2015). Further studies demonstrated an association of methylation of (cg06500161) locus in ABCG1 gene with its lower transcriptional activity, higher triglycerides level and higher triglycerides to HDL cholesterol ratio in 1941 obese individuals from four population-based European cohorts (Campanella et al. 2018). In our study we presented DNA hypermethylation in ABCG1 gene in new CpG locus (21:42219751–42219800) in leukocytes of patients with high LDL-CH.

We also found altered DNA methylation in patients with hypercholesterolemia, in key genes associated with fatty acid transport and metabolism (hypomethylated: PPARD, PPARG, SLC27A1, SLC27A3 and SLC25A20, and hypermethylated: ANGPTL4, ALCs6, ACADM and CPT1A). These results indicate inhibited β-oxidation as the gene CPT1A, coding for the key enzyme in the carnitine-dependent transport and ACADM encoding acyl-CoA dehydrogenase medium chain catalysing the initial step of fatty acid β-oxidation, are hypermethylated (GeneCards—the human gene database www.genecards.org) (Stelzer et al. 2016). Frazier-Wood et al. showed association of 2 CpGs (cg00574958, cg17058475) in 5′UTR to be associated with decreased number of VLDL particles whereas one (cg00574958) was associated with a decrease in small, dense subfraction of LDL (Frazier-Wood et al. 2014). They presented hypermethylation of 2 CpGs (cg00574958, cg17058475) in 5′UTR to be associated with decreased number of VLDL particles whereas one (cg00574958) was associated with a decrease in small, dense subfraction of LDL (Frazier-Wood et al. 2014). We presented DNA hypermethylation in new locus (11:68843060-68843119) located in the promoter of CPT1A gene in leukocytes of patients with high LDL-CH.

Interestingly, we identified differential methylation of genes coding for transcription factors important for lipid and glucose metabolism. The hypermethylated SREBF1, that regulates fatty acid and cholesterol metabolism and hypermethylated TCF7L2, important for glucose homeostasis, characterized hypercholesterolemic patients. Additionally the reduced methylation in transcription factors: KLF14 gene, previously associated with metabolism of HDL-CH, adipocyte function, and PPARD and PPAR- receptors for fatty acids was found (Florath et al. 2016; Dekkers et al. 2016; Vitali et al. 2017; Argmann et al. 2017; Varga et al. 2011).

Despite the observed epigenetic changes in hypercholesterolaemia, we cannot state in our studies if the differential methylation is a consequence rather that a cause of high blood lipids. Based on the regulated pathways in our study as well as relevant literature (Pfeiffer et al. 2015; Dekkers et al. 2016; Rangel-Salazar et al. 2011) we suggest that differential methylation observed in epigenome wide association studies is likely an mixed picture of sites that are the cause and consequence of abnormal lipids.

### Table 3 (continued)

| Description                  | p-value | Corr p-value | N | Hypermethylated               | Hypomethylated                                      |
|------------------------------|---------|--------------|---|------------------------------|-----------------------------------------------------|
| Transporter activity         | 1.44E−03| 1.01E−02     | 16| ABCB1 ABCC9 ABCG1 AMN AP2A2  | ABCB4 FASN ITPR1 SLC25A20 STARD3                   |
| Transcription factor binding | 1.26E−08| 3.54E−06     | 17| CTCF GATA4 EP300 LRP1 MED21  | ABCB1 ABCD5 ABCG1 AMN AP2A2                         |
| Transcription cofactor activity| 1.14E−05| 4.22E−04     | 11| CTCF EP300 LRP1 MED21 NCOA2  | ABCD5 ABCG1 AMN AP2A2 SLC27A1                       |
| Lipoprotein binding          | 1.21E−03| 9.26E−03     | 3 | LDLR LRP1                     | ABCD5 ABCG1 AMN AP2A2 SLC27A1                       |

Analyses performed using BINGO plugin in Cytoscape software. (a) Shows involvement of genes in biological processes and (b) in molecular function.
levels. This is in line with previous studies where it was showed that blood lipids level influence DNA methylation (Dekkers et al. 2016). Studies on VLR (very low density—VLDL and LDL—rich lipoproteins mix) in human THP-1 macrophages showed that they induces global de novo methylation (Rangel-Salazar et al. 2011). Extension of these studies revealed that human native VLDL and LDL-rich lipoprotein mix, induces decrease in pro-inflammatory and cholesterol transport gene expression in consequence of DNA methylation. For instance ABCG1 gene participating in cholesterol transport was down-regulated by VLR (Rangel-Salazar et al. 2011). Dekkers et al. analyzed genome wide DNA methylation in whole blood cells of 3296 individuals after Mendelian randomisation and demonstrated that higher LDL-CH induced higher methylation of a CpG (cg27168858) in DHCR24 gene. Moreover higher TG levels induced lower methylation of 2 CpGs (cg00574958, cg17058475), which were associated with higher expression of CPT1A. High TG levels were also accompanied by hypermethylation of CpG (cg11024682), which was associated with lower expression of SREBF1 gene. Additionally either lower TG or higher HDL-CH induced lower methylation of 2 CpGs (cg27243685, cg06500161), which was associated with higher expression of ABCG1 gene (Dekkers et al. 2016). On the contrary, in article by Pfeiffer et al. (Pfeiffer et al. 2015) DNA methylation in ABCG1, SREBF1 and CPT1A genes were presented rather as the cause not the consequence, of development of complex lipid-related diseases.

**Limitations**

The main limitation of our study was the limited number of samples for genome-wide DNA methylation analysis. Thus results from the high-throughput method give rise for further studies on targeted genes methylation in all samples from the large cohort. We assessed DNA methylation in peripheral blood because it is easily accessible and its collection is acceptable by patients. Although epigenetic studies on different tissue samples are more informative, blood samples are generally used in most studies with non-surgical subjects. Nevertheless, previous studies demonstrated that hypermethylated CpG islands: LEP, ADIPOQ in adipose tissue or PCSK9 in the liver overlap methylation status in the blood (Lohhoff et al. 2018; Houde et al. 2015). Additionally Crujeiras et al. (2016) demonstrated that DNA methylation map in circulating leukocytes reflects subcutaneous adipose tissue methylation pattern. This suggests that DNA methylation analysis in leukocytes may reflect a methylation profile in other tissues (liver, adipose tissue or intestine) relevant for the pathogenesis of lipid and lipoprotein disorders. Furthermore various types of leukocytes (monocytes, neutrophils, mast cells and B and T lymphocytes) are associated with atherosclerosis suggesting that may actively respond to hypercholesterolemia (Oguro 2019).

**Conclusions**

In conclusion, our preliminary data implies epigenetic regulation of lipids profile, demonstrated as differential DNA methylation in leukocytes of obese individuals with elevated LDL cholesterol levels. Analysis of DNA methylation microarrays indicated that the most regulated processes are lipoprotein plasma clearance and metabolism, reverse cholesterol transport and cholesterol efflux and fatty acid uptake and β-oxidation. Analysis of DNA methylation status in peripheral blood could be a tool for identifying the pathognomonic processes related to the hypercholesterolemia and other obesity related complications. As DNA methylation is reversible and dependent on environmental factors, that gives the potential to influence the methylation status of lipids genes by the nutrition and healthy lifestyle to prevent the obesity-related complications.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s10020-020-00220-z.

**Additional file 1: Table S1.** Detail results of identified differentially methylated CpG sites.

**Abbreviations**

AUC: Area under curves; BMI: Body mass index; CVD: Cardiovascular disease; FDR: False discovery rate; FGF19: Fibroblast growth factor 19; FGF21: Fibroblast growth factor 21; GIP: Glucose-dependent insulinotropic peptide; HDL: High density lipoprotein; HDL-CH: HDL cholesterol, HOMA-IR: Homeostasis Model Assessment Insulin Resistance; LDL: Low Density Lipoprotein; LDL-CH: LDL cholesterol; MBPs: Methyl-CpG binding proteins; MUFAs: Monounsaturated fatty acids; OGTT: Oral glucose tolerance test; OLTT: Oral lipid tolerance test; PUFAs: Polyunsaturated fatty acids; Q2: Median; (Q1; Q3): Interquartile range; SD: Standard deviation; TGs: Triglycerides; WHR: Waist-to-hip ratio.

**Acknowledgements**

The authors thank the patients for their cooperation. This research was supported in part by PL-Grid Infrastructure.

**Authors’ contributions**

TP performed DNA methylation study, analyzed and interpreted the data and drafted the manuscript. AP participated in conception and design of the study, analyzed the DNA methylation data and revised article critically for important intellectual content. JG interpreted the data and revised article critically for important intellectual content. UR performed the biochemical analyses. AG performed the biochemical analyses. BKW participated in conception and design of the study and recruited patients. PZ performed the biochemical analyses. MK performed the biochemical analyses. KSS performed the biochemical analyses. BS revised article critically for important intellectual content. ADK prepared the manuscript. MMM participated in conception and design of the study, recruited patients and revised article critically for important intellectual content. ADK performed the biochemical analyses. AP performed DNA methylation study, analyzed and interpreted the data and drafted the manuscript.
References

Abdul QA, Yu BP, Chung HY, Jung HA, Choi JS. Epigenetic modifications of gene expression by lifestyle and environment. Arch Pharmacol Res. 2017;40(11):1219–37.

Albuquerque D, Nóbrega C, Manco L, Padez C. The contribution of genetics and environment to obesity. Br Med Bull. 2017;123(1):159–73.

Ali O, Cerjak D, Kent JW, James R, Blangero J, Carless MA, et al. Methylation of Albuquerque D, Nóbrega C, Manco L, Padez C. The contribution of genetics and environment to obesity. Br Med Bull. 2017;123(1):159–73.

Guo SP, Houde AA, Breton E, Baillargeon JP, Perron P, Gaudet D, et al. DNA methylation at LRPI locus mediates the association between maternal total cholesterol changes in pregnancy and cord blood leptin levels. J Dev Orig Health Dis. 2020;11(4):369–78.

Guo Y, Lu Q, Xu D. Shedding light on FGF21: a potential negative regulator of PCSK9. Int J Cardiol. 2016;214:75–6. https://doi.org/10.1016/j.ijcard.2016.03.165.

Guo K, Eid SA, Elzinga SE, Pacut C, Feldman EL, Hur J. Genome-wide profiling of DNA methylation and gene expression identifies candidate genes for human diabetic nephropathy. Clin Epigenet. 2020;12(1):123.

Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med. 2010;16(1):7–16.

Houde AA, Légaré C, Biron S, Lescluse O, Biethor L, Marceau S, et al. Leptin and adiponectin DNA methylation levels in adipose tissues and blood cells are associated with BMI, waist girth and LDL-cholesterol levels in severely obese men and women. BMC Med Genet. 2015;16(1):29.

Houseman EA, Molitor J, Marsit CJ. Reference-free cell mixture adjustment in analysis of DNA methylation data. Bioinformatics. 2014;30(10):1431–9.

Johansen CB, Brans C, Bork-Jensen J, Ribe-Madsen R, Yang B, Lara E, et al. Effects of short-term high-fat overfeeding on genome-wide DNA methylation in the skeletal muscle of healthy young men. Diabetologia. 2012;55(12):3341–9.

Keating ST, El-Osta A. Epigenetics and metabolism. Circ Res. 2015;116(4):715–36.

Kim AY, Park YJ, Pan X, Shin KC, Kwak S-H, Bassas AF, et al. Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. Nat Commun. 2015;6:5785. https://doi.org/10.1038/ncomms6585.

Lohoff FW, Sorcher JL, Rosen AD, Mauro KL, Fanelli RR, Momenan R, et al. Methylation profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. Mol Psychiatry. 2018;23(9):1900–10.

Mach F, Bajgert C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification and inflammatory candidate genes and metabolic variables. J Mol Med. 2015;116(4):306–31.

Mittelstaedt K, Waldenberger M. DNA methylation in human lipid metabolism and related diseases. Curr Opin Lipidol. 2018;29(2):116–24.
Mulkearns EE, Cooper JA. FCH domain only-2 organizes clathrin-coated structures and interacts with Disabled-2 for low-density lipoprotein receptor endocytosis. Mol Biol Cell. 2012;23(7):1330–42. https://doi.org/10.1091/molcell.2011-09-0812.

Oguro H. The roles of cholesterol and its metabolites in normal and malignant hematopoiesis. Front Endocrinol. 2019;10(APR):1–15.

Pearse BM, Smith CJ, Owen DJ. Clathrin coat construction in endocytosis. Curr Opin Struct Biol. 2000;10(2):220–8.

Pedersen SD. Metabolic complications of obesity. Best Pract Res Clin Endocrinol. 2012;26(2):179–93. https://doi.org/10.1016/j.beem.2012.02.004.

Peterson AS, Fong LG, Young SG. Erratum: PCSK9 function and physiology. J Lipid Res. 2008;49(7):1595–9.

Pfeiffer L, Wahl S, Pilling LC, Reischl E, Sandling JK, Kunze S, et al. DNA methylation of lipid-related genes affects blood lipid levels. Circ Cardiovasc Genet. 2015;8(2):334–42.

Piening BD, Zhou W, Contrepois K, Röst H, Gu Urban GJ, Mishra T, et al. Integrative personal omics profiles during periods of weight gain and loss. Cell Syst. 2018;6(2):157–170.e8.

Rangel-Lindholm M, Aguilar-Salinas CA, Alvarado-Cau-Piening BD, Zhou W, Contrepois K, Röst H, Gu Urban GJ, Mishra T, et al. Reactome enhanced pathway visualization. Bioinformatics. 2017;33(21):3461–7.

Singaraju RR, Kang MH, Vaid K, Sanders SS, Vilas GL, Antsikaitis P, et al. Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. Circ Res. 2009;105(2):138–47.

Stelzer G, Rosen N, Plascshkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinform. 2016;54.3.1:30.1−1:30.33.

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA hyperlipidemia guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.

Stuart TJ, O'Neill K, Condon D, Sasson I, Sen P, Xia Y, et al. Diet-induced obesity alters the maternal metabolome and early placenta transcriptome and decreases placenta vascularity in the mouse. Biol Reprod. 2018,98(6):795–809.

Varga T, Czimermer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta Mol Basis Dis. 2011;1812(8):1007–22. https://doi.org/10.1016/j.bbadis.2011.02.014.

Vaugham AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res. 2006;47(11):2433–43.

Vitali C, Khetarpal SA, Rader DJ. hDL cholesterol metabolism and the risk of CHD: new insights from human genetics. Curr Cardiol Rep. 2017;19(12):132.

Wu X, Ge H, Baribault H, Gugte J, Weissmann J, Lemon B, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res. 2013;54(2):325–32.

Zhu YF, Huang YS, Li ZH, Zhang RM, Wang SR. Hypermethylation in promoter area of LDLR gene in atherosclerosis patients. Fen zi xi bing fu su hua. 2005;47(11):2433–43.

Zhou M, Marc Learned R, Rossi SJ, Tian H, DePaoli AM, Ling L. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J Lipid Res. 2019;60(3):550–65.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.